查看購物車
  • Simplified Chinese
  • English
  • Japanese
歐洲精準醫療市場（依生態系與國家）分析與預測（2024-2034）
市場調查報告書
商品編碼
1719318

歐洲精準醫療市場（依生態系與國家）分析與預測（2024-2034）

Europe Precision Medicine Market: Focus on Ecosystem and Country - Analysis and Forecast, 2024-2034
出版日期: | 出版商: BIS Research | 英文 83 Pages | 商品交期: 1-5個工作天內

價格

歐洲精準醫療市場規模預計將從 2024 年的 407.5 億美元成長到 2034 年的 1,187.9 億美元，預測期內（2024-2034 年）的複合年成長率為 11.29%。

基因組學、診斷學和標靶藥物的進步正在推動歐洲精準醫療領域的發展。主要促進因素包括慢性病的增加、數位健康資源的整合以及對個人化醫療的日益關注。政府計畫和研究合作夥伴支持定製藥物的研發，從而為患者帶來更多益處。此外，生物標記、次世代定序和人工智慧診斷的廣泛使用也正在改變罕見疾病、心臟病學和腫瘤學的治療。鑑於該地區強大的醫療基礎設施和日益增強的個人化治療意識，精準醫療正在整個醫療環境中迅速應用。

主要市場統計數據
預測期 2024-2034
2024年評估 407.5億美元
2034年的預測 1187.9億美元
複合年成長率 11.29%

從治療方法到高度客製化的治療方法，歐洲精準醫療市場正在大幅改變醫療保健格局。技術進步，特別是基因組學、次世代定序和生物標記識別領域的技術進步，使得診斷和治療疾病的方法更加專業化。個人化醫療正在顯著改善罕見遺傳疾病、心血管疾病和腫瘤患者的治療效果。歐洲各國政府透過推行積極的政策和大力投資研發，為這項變革做出了貢獻。監管機構正在加快精準醫療的核准流程，同時對病患隱私和資料安全保持嚴格的指導方針。

製藥公司、生技公司和學術機構之間的策略聯盟進一步加強了市場，培育了創新和合作研究的生態系統。數位健康工具和人工智慧擴大被融入臨床工作流程中，以提高診斷準確性並客製化治療。儘管面臨先進技術高成本、監管複雜以及需要強大的醫療保健基礎設施等挑戰，精準醫療的發展勢頭依然強勁。在公共資金和私人投資的支持下，歐洲致力於個人化醫療，正在重新定義臨床實踐，並將自己定位為提供以患者為中心的醫療保健的全球領導者。

遺傳學、人工智慧和醫療技術的進步使得個人化治療方案成為可能，推動歐洲精準醫療業務的快速發展。特別是在腫瘤學和罕見疾病領域，次世代定序與生物標記開發相結合，有助於早期發現和加護治療。由於政府計劃、醫療創新資金增加以及合作研究活動，市場正在擴大。由於人口老化、慢性病盛行率上升以及對更有效治療方案的需求，市場正在成長。然而，高成本、複雜的法律體制和資料隱私問題阻礙了其廣泛採用。將精準醫療納入傳統醫療保健系統需要大量的基礎設施投資和病患教育。儘管存在這些障礙，但技術發展以及生物技術、製藥和學術機構之間的策略聯盟正在為更具凝聚力和更有效的精準醫療生態系統打開大門。

產品/創新策略：本報告深入探討精準醫療領域的最新技術進步，使公司能夠推動創新並開發符合市場需求的尖端產品。

成長/行銷策略：我們提供全面的市場分析並確定關鍵的成長機會，為您的組織提供製定有針對性的行銷策略和有效擴大市場影響力的知識。

競爭策略：徹底分析競爭格局有助於了解競爭對手的優勢和劣勢，並有助於制定有效的策略以獲得市場競爭優勢。

本報告研究了歐洲精準醫療市場，提供了市場概況、生態系統和國家趨勢以及參與市場的公司概況。

目錄

第1章 市場概述

  • 市場定義
  • 精準醫療：創造以病人為中心的醫療的前沿
  • 精準醫療：重新構想「一刀切」的治療方法，實現個人治療方法
  • 舉措和計劃
  • 精準醫療：實行技術與應用

第2章市場：產業展望

  • 精準醫療市場：生態系分析
  • 市場趨勢
  • 業界考察
  • 生態系摘要

第3章 區域

  • 概述
  • 歐洲
    • 區域概況
    • 市場成長動力
    • 成長抑制因素
    • 德國
    • 法國
    • 義大利
    • 英國
    • 西班牙
    • 其他

第4章 競爭格局

  • 競爭格局
  • 公司簡介
    • Almac Group
    • ANGLE plc
    • F. Hoffmann-La Roche Ltd.
    • Merck KGaA
    • QIAGEN NV
    • bioMerieux SA
    • Sanofi SA
    • Randox Laboratories Ltd.
    • GSK plc
    • Novartis AG
    • Menarini Silicon Biosystems

第5章調查方法

Product Code: BHP2770SS

Introduction to Europe Precision Medicine Market

The Europe precision medicine market is projected to reach $118.79 billion by 2034 from $40.75 billion in 2024, at a CAGR of 11.29% during the forecast period of 2024-2034. Advances in genomes, diagnostics, and targeted medicines are driving the precision medicine sector in Europe. Key factors include the growing prevalence of chronic diseases, the integration of digital health resources, and an increased emphasis on personalised healthcare. The creation of customised medicines is being aided by government programs and research partnerships, which is increasing patient results. Furthermore, the care of uncommon illnesses, cardiology, and oncology is changing due to the extensive use of biomarkers, next-generation sequencing, and AI-powered diagnostics. Precision medicine is being adopted more quickly in a variety of healthcare settings thanks to the region's robust healthcare infrastructure and rising awareness of personalised treatment.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2024 - 2034
2024 Evaluation$40.75 Billion
2034 Forecast$118.79 Billion
CAGR11.29%

From one-size-fits-all therapies to highly customised therapeutic options, the precision medicine market in Europe is drastically changing the healthcare environment. More specialised methods of diagnosing and treating diseases have been made possible by technological advancements, especially in the fields of genomics, next-generation sequencing, and biomarker identification. Personalised therapies are greatly improving patient outcomes in uncommon genetic disorders, cardiovascular diseases, and oncology. By promoting policies that are helpful and making significant investments in research and development, European governments have been instrumental in this change. While maintaining strict guidelines for patient privacy and data security, regulatory bodies are expediting the approval procedures for precision treatments.

The market is further bolstered by strategic alliances among pharmaceutical companies, biotech firms, and academic institutions, fostering an ecosystem of innovation and collaborative research. Digital health tools and artificial intelligence are increasingly integrated into clinical workflows, enhancing diagnostic accuracy and treatment customization. Despite challenges such as the high cost of advanced technologies, regulatory complexities, and the need for robust healthcare infrastructure, the momentum behind precision medicine remains strong. Europe's commitment to personalized healthcare, underpinned by public funding and private investment, positions the region as a global leader in redefining clinical practices and delivering patient-centric care.

Market Segmentation

Segmentation 1: by Ecosystem

  • Applied Science
  • Precision Diagnostics
  • Digital Health and Information Technology
  • Precision Therapeutics

Segmentation 2: by Region

  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe

Market Trends, Drivers and Challenges of Europe Precision Medicine Market

Advances in genetics, artificial intelligence, and health technology that allow for individualised treatment options are driving a rapid evolution of the precision medicine business in Europe. Especially in oncology and uncommon disorders, the combination of next-generation sequencing and biomarker development is promoting early detection and focused treatments. The market is expanding thanks to government programs, more financing for healthcare innovation, and cooperative research activities. The market is expanding due to ageing populations, an increase in the prevalence of chronic diseases, and a need for more efficient treatment plans. However, obstacles to wider adoption include expensive costs, intricate legal frameworks, and data privacy issues. It takes large infrastructure investments and patient education to incorporate precision medicine into traditional healthcare systems. Notwithstanding these obstacles, technological developments and strategic alliances between biotech, pharmaceutical, and academic organisations are opening the door to a more cohesive and effective precision medicine ecosystem, which will eventually lead to better patient outcomes and a shift in Europe towards individualised healthcare solutions.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in precision medicine, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Almac Group Ltd.
  • ANGLE plc
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • QIAGEN N.V.

Table of Contents

1 Market Overview

  • 1.1 Market Definition
  • 1.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine
  • 1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
  • 1.4 Initiatives and Programs
  • 1.5 Precision Medicine: Enabling Technologies and Applications
    • 1.5.1 Innovators
      • 1.5.1.1 3D DNA Printing
        • 1.5.1.1.1 Introduction
        • 1.5.1.1.2 Role of 3D DNA Printing
      • 1.5.1.2 RNA-Seq
        • 1.5.1.2.1 Introduction
        • 1.5.1.2.2 Role of RNA-Seq in Precision Medicine
        • 1.5.1.2.3 Key Players
      • 1.5.1.3 4D Molecular Imaging
        • 1.5.1.3.1 Introduction
        • 1.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
        • 1.5.1.3.3 Key Players
    • 1.5.2 Early Adopters
      • 1.5.2.1 CRISPR
        • 1.5.2.1.1 Introduction
        • 1.5.2.1.2 Role of CRISPR in Precision Medicine
        • 1.5.2.1.3 Key Players
      • 1.5.2.2 Blockchain
        • 1.5.2.2.1 Introduction
        • 1.5.2.2.2 Role of Blockchain in Precision Medicine
        • 1.5.2.2.3 Key Players
      • 1.5.2.3 Imaging Informatics
        • 1.5.2.3.1 Introduction
        • 1.5.2.3.2 Role of Imaging Informatics in Precision Medicine
        • 1.5.2.3.3 Key Players
    • 1.5.3 Early Majority
      • 1.5.3.1 Artificial Intelligence (AI)
        • 1.5.3.1.1 Introduction
        • 1.5.3.1.2 Role of Artificial Intelligence in Precision Medicine
        • 1.5.3.1.3 Key Players
      • 1.5.3.2 Circulating Free DNA (cfDNA)
        • 1.5.3.2.1 Introduction
        • 1.5.3.2.2 Role of cfDNA in Precision Medicine
        • 1.5.3.2.3 Key Players
      • 1.5.3.3 Big Data
        • 1.5.3.3.1 Introduction
        • 1.5.3.3.2 Role of Big Data in Precision Medicine
        • 1.5.3.3.3 Key Players
      • 1.5.3.4 Next-Generation Sequencing (NGS)
        • 1.5.3.4.1 Introduction
        • 1.5.3.4.2 Role of NGS in Precision Medicine
        • 1.5.3.4.3 Key Players
      • 1.5.3.5 Health Informatics
        • 1.5.3.5.1 Introduction
        • 1.5.3.5.2 Role of Health Informatics in Precision Medicine
        • 1.5.3.5.3 Key players
      • 1.5.3.6 Bioinformatics
        • 1.5.3.6.1 Introduction
        • 1.5.3.6.2 Role of Bioinformatics in Precision Medicine
        • 1.5.3.6.3 Key Players
    • 1.5.4 Late Majority
      • 1.5.4.1 Polymerase Chain Reactions (PCR)
        • 1.5.4.1.1 Introduction
        • 1.5.4.1.2 Role of PCR in Precision Medicine
        • 1.5.4.1.3 Key players
      • 1.5.4.2 Microarray
        • 1.5.4.2.1 Role of Microarray in Precision Medicine
        • 1.5.4.2.2 Key Players

2 Market: Industry Outlook

  • 2.1 Precision Medicine Market: Ecosystem Analysis
  • 2.2 Market Trends
    • 2.2.1 Integrating Advanced Imaging for Enhanced Diagnostics and Treatment
    • 2.2.2 Emergence of Biobanks as a Cornerstone of Precision Medicine
  • 2.3 Industry Insights
    • 2.3.1 Patent Analysis
    • 2.3.2 Pipeline Analysis
    • 2.3.3 Legal Requirements and Framework by the EMA
  • 2.4 Ecosystem Summary

3 Region

  • 3.1 Overview
  • 3.2 Europe
    • 3.2.1 Regional Overview
    • 3.2.2 Driving Factors for Market Growth
    • 3.2.3 Factors Challenging the Market
      • 3.2.3.1 Europe Precision Medicine Market (by Ecosystem),
    • 3.2.4 Germany
      • 3.2.4.1 Germany Precision Medicine Market (by Ecosystem),
    • 3.2.5 France
      • 3.2.5.1 France Precision Medicine Market (by Ecosystem)
    • 3.2.6 Italy
      • 3.2.6.1 Italy Precision Medicine Market (by Ecosystem),
    • 3.2.7 U.K.
      • 3.2.7.1 U.K. Precision Medicine Market (by Ecosystem),
    • 3.2.8 Spain
      • 3.2.8.1 Spain. Precision Medicine Market (by Ecosystem),
    • 3.2.9 Rest-of-Europe
      • 3.2.9.1 Rest-of-Europe Precision Medicine Market (by Ecosystem)

4 Competitive Landscape

  • 4.1 Competitive Landscape
    • 4.1.1 Synergistic Activities
  • 4.2 Company Profiles
    • 4.2.1 Almac Group
      • 4.2.1.1 Overview
      • 4.2.1.2 Top Products/Services
      • 4.2.1.3 Top Competitors
      • 4.2.1.4 Analyst View
    • 4.2.2 ANGLE plc
      • 4.2.2.1 Overview
      • 4.2.2.2 Top Products
      • 4.2.2.3 Top Competitors
      • 4.2.2.4 Analyst View
    • 4.2.3 F. Hoffmann-La Roche Ltd.
      • 4.2.3.1 Overview
      • 4.2.3.2 Top Products
      • 4.2.3.3 Top Competitors
      • 4.2.3.4 Analyst View
    • 4.2.4 Merck KGaA
      • 4.2.4.1 Overview
      • 4.2.4.2 Top Products
      • 4.2.4.3 Top Competitors
      • 4.2.4.4 Analyst View
    • 4.2.5 QIAGEN N.V.
      • 4.2.5.1 Overview
      • 4.2.5.2 Top Products
      • 4.2.5.3 Top Competitors
      • 4.2.5.4 Analyst View
    • 4.2.6 bioMerieux SA
      • 4.2.6.1 Overview
      • 4.2.6.2 Top Products
      • 4.2.6.3 Top Competitors
      • 4.2.6.4 Analyst View
    • 4.2.7 Sanofi S.A.
      • 4.2.7.1 Overview
      • 4.2.7.2 Top Products
      • 4.2.7.3 Top Competitors
      • 4.2.7.4 Analyst View
    • 4.2.8 Randox Laboratories Ltd.
      • 4.2.8.1 Overview
      • 4.2.8.2 Top Products
      • 4.2.8.3 Top Competitors
      • 4.2.8.4 Analyst View
    • 4.2.9 GSK plc
      • 4.2.9.1 Overview
      • 4.2.9.2 Top Products
      • 4.2.9.3 Top Competitors
      • 4.2.9.4 Analyst View
    • 4.2.10 Novartis AG
      • 4.2.10.1 Overview
      • 4.2.10.2 Top Products
      • 4.2.10.3 Top Competitors
      • 4.2.10.4 Analyst View
    • 4.2.11 Menarini Silicon Biosystems
      • 4.2.11.1 Overview
      • 4.2.11.2 Top Products
      • 4.2.11.3 Top Competitors
      • 4.2.11.4 Analyst View

5 Research Methodology

  • 5.1 Precision Medicine Market: Research Methodology
    • 5.1.1 Data Sources
      • 5.1.1.1 Primary Data Sources
      • 5.1.1.2 Secondary Data Sources
    • 5.1.2 Data Triangulation
  • 5.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Europe Precision Medicine Market, $Billion, 2023, 2028, and 2034
  • Figure 2: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure
  • Figure 3: Precision Medicine - a Multi-Faceted Approach to Patient Care
  • Figure 4: Decreasing Cost ($) and Increasing Output (TB) of Genome Sequencing, 2009-2025
  • Figure 5: Precision Medicine Market (by Region), $Billion, 2023, 2028, and 2034
  • Figure 6: Europe Precision Medicine Market (by Ecosystem), $Billion, 2023, 2028, and 2034
  • Figure 7: Precision Medicine Approach
  • Figure 8: Evolution of Precision Medicine Technology
  • Figure 9: Precision Medicine: Enabling Technologies and Applications
  • Figure 10: Structured Big Data Reporting Benefits
  • Figure 11: Generalized Process for the Microarray
  • Figure 12: Stakeholders in Precision Medicine
  • Figure 13: Number of Patents Files, 2020-2024
  • Figure 14: Precision Medicine by Top Patent Owner
  • Figure 15: Europe Precision Medicine Market, $Billion, 2023-2034
  • Figure 16: Germany Precision Medicine Market, $Billion, 2023-2034
  • Figure 17: France Precision Medicine Market, $Billion, 2023-2034
  • Figure 18: Italy Precision Medicine Market, $Billion, 2023-2034
  • Figure 19: U.K. Precision Medicine Market, $Billion, 2023-2034
  • Figure 20: Spain Precision Medicine Market, $Billion, 2023-2034
  • Figure 21: Rest of Europe Precision Medicine Market, $Billion, 2023-2034
  • Figure 22: Synergistic Activities, by Company (January 2020- January 2025)
  • Figure 23: Synergistic Activities, by Type (January 2020- January 2025)
  • Figure 24: Data Triangulation
  • Figure 25: Top-Down and Bottom-Up Approach

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Application
  • Table 3: Pipeline Analysis (by Company)
  • Table 4: Pipeline Analysis (by Product)
  • Table 5: Precision Medicine Drugs Pipeline Analysis
  • Table 6: Ecosystem Summary
  • Table 7: Precision Medicine Market (by Region), $Million, 2023-2034
  • Table 8: Europe Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 9: Germany Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 10: France Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 11: Italy Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 12: Funding Scenario in Universities
  • Table 13: U.K. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 14: Spain. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
  • Table 15: Rest-of-Europe Precision Medicine Market (by Ecosystem), $Billion, 2023-2034